JAK2 and acute lymphoblastic leukemia: Fifty percent of CRLF2-rearranged Down syndrome–associated ALL cases have concomitant JAK mutations (commonly a JAK2 R683G point mutation)83, but JAK inhibitors have yet to be formally evaluated in clinical trials.